New Data Reveal That Presence of Metastases at Initial Prostate Cancer Diagnosis May Have a Critical Impact on Prognosis for Metastatic Castration-Resistant Patients
Janssen-Cilag International NV today announced that data from an interim analysis of The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration-resistant prostate cancer (mCRPC), indicate that the presence of distant metastases (M1) at initial diagnosis may be a critical indicator of future treatment and prognosis for mCRPC patients.
The data, presented today at the American Society of Clinical Oncology (ASCO) 2016 Congress, Chicago, USA, described characteristics at study entry of men with mCRPC who had distant metastases at primary diagnosis (M1) as compared to those whose cancer had not metastasised at primary diagnosis (M0). The data demonstrated higher prostate-specific antigen (PSA) levels, increased incidence of bone lesions and slightly worse level of functioning, in terms of their ability to care for themselves, daily activity, and physical ability (measured by ECOG Scale of Performance Status) for patients with M1 at initial diagnosis compared to patients with no metastases (M0) at initial diagnosis.
- PSA levels were 34.4% higher (61.7 ng/mL vs 45.9 ng/mL) for M1 vs M0
- Incidence of bone lesions (>5) were 24% higher (51% vs 41%) for M1 vs M0
- ECOG Scale of Performance Status >2 were higher (17% vs 13%) for M1 vs M0
“These data can help to better inform the way we treat mCRPC patients. It demonstrates that patients who present with metastases at diagnosis require particularly close attention from healthcare professionals to tackle the disease head on with prompt and effective treatment for the best possible outcome,” said Dr Simon Chowdhury, Guy’s Hospital, London. “Real world data, such as these, provide us with valuable insight into the true patient journey. They include a wider population, such as men of a broader age range and with other existing health problems, than the more restricted and closely monitored populations seen in interventional clinical trials.”
The Prostate Cancer Registry has enrolled over 3,000 mCRPC patients in 199 centres across 16 European countries. It aims to address the key medical and scientific questions concerning the optimal care of mCRPC patients in routine practice. The size of the database will enable analysis on sub-populations relevant to healthcare professionals. In this dataset, 1323 patients with mCRPC were analysed, including 549 who had M1 (41.5%) and 526 who had M0 (39.8%) disease at initial diagnosis, and 248 men for whom state of metastasis was not measureable (Mx, 18.7%) at initial diagnosis. Follow-up of these patients over time will clarify how these clinical differences and subsequent treatment may affect clinical outcome.
Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA) said: “Janssen is proud to be supporting The Prostate Cancer Registry, which is the largest of its kind in Europe. As there is currently limited data available on the everyday experience of mCRPC patients we hope that the insights from the trial will lead to an improvement in the quality of care and prognosis for men with mCRPC.”
Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe each year.2 Latest prostate cancer figures show that there are currently three million men living with the disease in Europe.3
NOTES TO EDITORS
About The Prostate Cancer Registry
The Prostate Cancer Registry was initiated in 2013 as a long-term commitment by Janssen to address optimal treatment of mCRPC in routine practice. The Registry was designed in consultation with specialists in mCRPC and examines patients being managed in a range of oncology and urology settings, with the aim of reflecting routine clinical practice.
Patients are enrolled upon initiating a mCRPC treatment or a period of surveillance, defined as not currently receiving an active treatment for castration resistance. The Registry is collecting data on a pan-European scale on patient demography and status, treatment sequencing and effectiveness, ongoing disease management, quality of life, medical resource utilisation and outcomes.
The first analysis was presented at the 2015 European Cancer Congress (ECC) in Vienna Austria and final analysis is planned for 2019.
Janssen-Cilag International NV is one of the Janssen Pharmaceutical Companies. Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
Janssen in Oncology
In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include disease area strongholds that focus on haematologic malignancies and prostate cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.
1 Chowdhury S et al. The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis? Poster presented at the American Society of Clinical Oncology (ASCO) 2016 Congress, 4 June, Chicago, USA. Poster Presentation. ASCO abstract #5024. Available at: http://abstract.asco.org/176/AbstView_176_161487.html. Last accessed May 2016.
2 Ferlay J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013; 49: p1374–1403.
3 European Commission. CORDIS Express: Prevention, diagnosis and treatment of prostate cancer. Available at: http://cordis.europa.eu/news/rcn/122705_en.html. Last accessed September 2015.
+44 (0)7876 394 360
Phone: +1 (0)732 524 3922
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Smiths Detection Technology Deployed for NATO Summit Security17.7.2018 08:17 | Pressemelding
Smiths Detection technology supported the security operations surrounding the NATO Summit in Brussels on 11th/12th July. A range of solutions were deployed by the European Commission Counter-Terrorism Unit and Belgian Federal Police at Brussels Airport and various key locations around the city to detect potential threats from explosives, chemicals and radiation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180717005386/en/ Smiths Detection Technology Deployed for NATO Summit Security Three different types of trace detectors were used during the summit: TRACE-PRO to reveal traces of explosives on people, vehicles and surfaces; LCD personal chemical detectors; and the portable, desktop IONSCAN 600, which detects and identifies trace amounts of both explosives and narcotics. Hand-held RadSeeker and HazMatID Elite systems were also deployed to detect and identify any nuclear threat materials as well as liquid and solid chemica
The European Project AMable Launches Its First Open Call17.7.2018 08:00 | Pressemelding
The European Project AMable has launched its First Open Call to find innovative ideas for additively manufactured products. The selected teams will be supported by AMable to develop an idea towards a final product by offering the services across all steps from design to finish. As a Factories of the Future (FoF) project participating in I4MS (ICT for Manufacturing SMEs) and with the support of the European Union's Horizon 2020 research and innovation programme, the aim of AMable project is to accelerate the uptake of additive manufacturing (AM) technologies; from design to manufacture for functional parts throughout the European Union. AMable is creating a digital framework to provide impartial access to the best European AM knowledge to support this adoption. This knowledge will be offered as advanced and tailored services to assist SMEs in the uptake of AM and include technological, business and training services. For this Open Call, the European Project is looking for original ideas
More Than Half of Sub-Saharan Africa to Be Connected to Mobile by 2025, Finds New GSMA Study17.7.2018 07:00 | Pressemelding
More than half the population of Sub-Saharan Africa will be subscribed to a mobile service by 2025, according to the latest edition of the GSMA’s Mobile Economy report series, published at the GSMA ‘Mobile 360 – Africa’ event being held in Kigali this week. The new report forecasts that there will be 634 million unique mobile subscribers1 across Sub-Saharan Africa by 2025, equivalent to 52 per cent of the population, up from 444 million (44 per cent) at the end of last year. The report also calculates that the mobile ecosystem will add more than $150 billion in value to Sub-Saharan Africa’s economy by 2022, equivalent to almost 8 per cent of regional GDP. “For many citizens across the region, particularly those living in rural areas, a mobile phone is not just a communications device but also the primary channel for getting online and a vital tool for improving their lives,” commented John Giusti, Chief Regulatory Officer at the GSMA. “More needs to be done to extend connectivity to th
Norsk Titanium Marks Milestone in U.S. Production17.7.2018 07:00 | Pressemelding
The University of Notre Dame Turbomachinery Laboratory (NDTL), Norsk Titanium US, Inc. (Norsk), Pratt & Whitney and TURBOCAM International are collaborating to develop and test additively manufactured turbomachinery components. This collaboration will focus on exploring the applicability of Norsk’s Rapid Plasma Deposition™ (RPD™) material to turbomachinery applications. As part of this effort, NDTL will test an additively manufactured integrally bladed rotor (IBR) produced and inspected to meet the applicable quality specifications used in Pratt & Whitney’s current turbomachinery components. The team has completed the initial phase of testing, with TURBOCAM International conducting machining trials of Norsk’s RPD™ material, and Pratt & Whitney successfully inspecting the material to the same specification as forged turbomachinery components. The material’s manufacturing qualities were evaluated for applicability to TURBOCAM’s precision milling processes. “We were very pleased with the
GSMA Finds That Consumers in Developing Countries Are Hard Hit by High Spectrum Prices17.7.2018 06:00 | Pressemelding
Better spectrum pricing policies are needed in developing countries to improve the economic and social welfare of the billions of people that remain unconnected to mobile broadband services, according to a new report, ‘Spectrum Pricing in Developing Countries’, released by the GSMA today at the Mobile 360 – Africa conference in Kigali. The study reveals that spectrum prices in developing countries are, on average, more than three times higher than in developed countries, when income is taken into account. This high spectrum pricing is a major roadblock to increasing mobile penetration. Authored by GSMA Intelligence, the study also found that governments are playing an active role in increasing spectrum prices to maximise state revenues from spectrum licensing. High spectrum prices are linked to countries with high levels of sovereign debt, and alarmingly average reserve prices in spectrum auctions are more than five times higher in developing countries than in developed, once income is
NEC and dotData Use AI to Accelerate Data Science for the SMBC Group17.7.2018 04:38 | Pressemelding
NEC Corporation (NEC) (TOKYO:6701) and dotData, Inc., a Silicon Valley venture in the automation of data science, today announced the provision and full operation of “dotData” platform for the Sumitomo Mitsui Financial Group, Inc. (SMBC Group) in order to strengthen the Group’s analytical capabilities. In recent years, the need for big data analytics has been growing rapidly. However, there is also an increasing shortage of data scientists to handle this need. In order to address this issue, dotData automates data science processes through artificial intelligence (AI). dotData platform is now commercially available globally. NEC has obtained an exclusive license from dotData to provide this software across Japan. Sumitomo Mitsui Banking Corporation, NEC and the dotData team have actively worked to incorporate AI into banking operations in order to create new service offerings since 2016. Following this success, the SMBC Group is now expanding the provision of dotData platform throughou